Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Are you in your 20s and wondering if a financial advisor is right for you? Learn who should consider seeking professional financial help.
26,867 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Suburban homeowners and renters are rethinking political loyalties as housing costs bite and local zoning fights esca...
Netflix walked away from a blockbuster deal, yet it still raised prices. This personal-finance guide explains what ha...
Gas prices are pushing households to rely more on credit as fuel costs take a larger share of income. The trend shows...
The crypto world is buzzing about XRP and a potential 90% plunge. This article breaks down the history, risk factors,...
Variant has closed a $222 million fund to back early-stage startups at the intersection of AI, crypto, and autonomy. ...
A 160-year naming split between soccer and football continues to ripple through branding, sponsorships, and consumer ...
When high-level insiders transact, it sparks questions. This article explains what medical's general counsel sells si...
A real-world look at a funding controversy that affected a community food program and what it means for donors and ho...
A high-profile insider move has many ALAB investors wondering what comes next. This article breaks down the $60.5 mil...
SpaceX is rumored to pursue a summer IPO valued at about $1.5 trillion, a move that would reshape public market norms...
A top Interface executive dumped stock in a move worth hundreds of thousands. Is this a signal about the business or ...